Tag:
colorectal cancer
Latest Headlines
Latest Headlines
Investors punish Exact Sciences despite positive data
Exact Sciences stock plunged more than 20% late Thursday morning based on what was ostensibly positive early news about a massive pivotal study for the company's colorectal cancer molecular diagnostic test. While the data met all endpoints, investors clearly wanted better and they punished the company as a result.
New radiation therapy companion Dx in the works
Cancer diagnostics startup CvergenX will work jointly with the National Cancer Institute to develop a new diagnostic that would predict the likely success of radiation therapy. The goal is to bring the test to market within three years.
U.K. team concocts rapid approach for colorectal cancer biomarker detection
U.K. scientists came up with a way to more efficiently detect a crucial colorectal cancer biomarker. They've even created a new word to describe the diagnostic process: "spinostics."
MIT's nanoparticles make cancer biomarkers more visible
Researchers at MIT have found a nanoparticle solution that can ramp up biomarker production and make cancer diagnostics a little easier
Exact Sciences heads to the FDA with cancer diagnostic
Fresh off some promising data for its stool-based cancer diagnostic, Exact Sciences is knocking on the FDA's door for full approval, filing part one of a three-step PMA for the assay.
Aspirin boosts survival in colorectal cancer mutation
A treatment as cheap and simple as aspirin can make some patients with colorectal cancer live longer, but it doesn't work for everyone. Researchers from the U.S. and Japan have pinpointed a mutation in a single gene that could find the patients that this could help.
Screening for colorectal cancer is an exact science
Data on Exact Sciences' colorectal cancer screening test suggest that the assay could pick up the DNA changes and traces of blood that signal precancers and the very earliest stages of cancer, when treatment is at its most effective.
Timeline on regorafenib (Stivarga) development
Three months after landing FDA fast-track review status for regorafenib , Bayer 's top cancer prospect, today the agency delivered an approval as a treatment for colorectal cancer . The approval comes after a tumultuous lawsuit filed in 2009 by Onyx Pharmaceuticals ( $ONXX ), claiming the compound can be distinguished from Nexavar by only a single atom. Here's a look back at regorafenib's history.
UPDATED: Bayer, Onyx nab speedy FDA OK for regorafenib, prices at $9,350
Only three months after nabbing FDA fast-track review status for regorafenib, Bayer's top cancer prospect, the agency handed out a speedy approval this afternoon as a new treatment for metastatic colorectal cancer. The double-quick regulatory OK completes Bayer's quick sprint through the late-stage development process, paving the way to commercialization work expected to generate peak sales of $1.25 billion a year or more.
Genes power bowel cancer marker panel
A group of Spanish institutions are collaborating to develop an early test for colorectal cancer, the second-highest cause of cancer death in the Western world, killing 50,000 people every year.
